8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A clinical review of semaglutide 2.4 mg (Wegovy) dose adjustments, pharmacogenomics, and outcomes data specific to Black and African ancestry patients, with ethnicity-stratified trial subgroups and guideline context.
Semaglutide 2.4 mg (Wegovy) produces smaller absolute weight-loss percentages in East Asian trial cohorts than in the predominantly White STEP-1 population, but the metabolic benefit per kilogram lost may be comparable or greater. This article separates what STEP-6 actually showed from what remains extrapolated.
A clinician-focused review of semaglutide 2.4 mg dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, ethnicity-stratified trial data, and practical titration guidance.
A clinical deep-dive into semaglutide 2.4 mg dosing for Hispanic and Latino patients, covering ethnicity-stratified STEP trial subgroups, pharmacogenomics, insulin resistance phenotypes, and practical titration guidance.
A clinical deep-dive into documented efficacy gaps, subgroup RCT data, pharmacogenomics, and dosing considerations for Wegovy (semaglutide 2.4 mg) in Black and African ancestry patients.
South Asian patients using Wegovy (semaglutide 2.4 mg) may see smaller percentage weight loss than trial averages suggest. Here is what ethnicity-stratified subgroup data, pharmacogenomic research, and revised BMI thresholds tell clinicians and patients.
Evidence-based guide to Wegovy (semaglutide 2.4 mg) dosing considerations for South Asian patients, including BMI thresholds, pharmacogenomic factors, and titration guidance.
A guide to how semaglutide 2.4 mg (Wegovy) performs in South Asian patients, covering ethnicity-specific BMI thresholds, pharmacogenomics, GI tolerability, cardiovascular risk, and dosing considerations backed by trial subgroup data.